The CELTIC Bifurcation study will examine outcomes for patients treated by planned culotte stenting and compare outcomes with 2 different stent platforms, the next generation Synergy II and the Xience Xpedition DES platforms.
ClinicalTrials.gov ID: NCT02232815
Sponsor
Sponsored by Supported by
 |  |
Primary endpoints
Composite measure of Adverse events [ Time Frame: 9 months ]
Composite of: Death, Myocardial Infarction, CVA, Target Vessel Failure (Composite of Target Vessel Revascularization and Target Vessel Inadequacy), Definite or Probable stent thrombosis (ARC criteria [14]), Binary angiographic restenosis
CERC Services
- Full Services
Countries
Ireland, UK
Number of investigational sites
9
Number of patients
170
